CN100400082C - Pharmaceutical composition for treating acute gout and its extraction method - Google Patents

Pharmaceutical composition for treating acute gout and its extraction method Download PDF

Info

Publication number
CN100400082C
CN100400082C CNB2005100390408A CN200510039040A CN100400082C CN 100400082 C CN100400082 C CN 100400082C CN B2005100390408 A CNB2005100390408 A CN B2005100390408A CN 200510039040 A CN200510039040 A CN 200510039040A CN 100400082 C CN100400082 C CN 100400082C
Authority
CN
China
Prior art keywords
extract
iii
saponin
volatile oil
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CNB2005100390408A
Other languages
Chinese (zh)
Other versions
CN1698858A (en
Inventor
尹莲
史欣德
徐立
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing University of Chinese Medicine
Original Assignee
Nanjing University of Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing University of Chinese Medicine filed Critical Nanjing University of Chinese Medicine
Priority to CNB2005100390408A priority Critical patent/CN100400082C/en
Publication of CN1698858A publication Critical patent/CN1698858A/en
Application granted granted Critical
Publication of CN100400082C publication Critical patent/CN100400082C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a medicinal composition for treating acute gout and an extraction method thereof. The composition is prepared from the extract of effective ingredients in the raw medicinal materials of phellodendron bark, atractylodes rhizome, achyranthes, coix seed, glabrous greenbrier rhizome and homeysuckle stem, namely alkaloid, volatilization, saponin, organic acid, flavone and water saccharide according to a certain proportion. The medicinal composition has obvious therapeutic effect on resisting inflammation, relieving pain and lowering uric acid through pharmacodynamic tests. The effective rate of treating acute gout in clinical treatment is 100%, the uric acid can be lowered to a normal level with safety and no toxicity, and thus, the present invention is an ideal medicine for treating acute gout.

Description

A kind of pharmaceutical composition and extracting method thereof for the treatment of acute gout
One, technical field:
The present invention relates to the field of Chinese medicines, specifically relate to a kind of compositions and extracting method thereof for the treatment of the drug extract of acute gout.
Two, background technology
Gout is because long-term purine metabolic disturbance or urate excretion reduce a kind of clinical syndrome that causes.Its characteristics are that hyperuricemia, characteristic acute arthritis are shown effect repeatedly, tophus deposits, the tophus chronic arthritis.Aspect western medical treatment, two purposes that the treatment gout need reach have been proposed: in time control the acute attack of gouty arthritis; The long-term treatment hyperuricemia, prevention urate deposition and gout acute relapse promote tophaceous absorption.And Western medicine is at three kinds of selected medicines of acute attack stage: colchicine, NSAID (non-steroidal anti-inflammatory drug) and adrenocortical hormone, though the anti-inflammatory analgetic effect is fast, but medical expense height, in anti-inflammatory analgesic, there is not the uric acid resisting effect, and the most drug toxic and side effects is also quite obvious, effective dose as colchicine is close with the dosage that produces gastrointestinal symptoms such as diarrhoea, also has systemic adverse reactions, as bone marrow depression, hepatorenal damage, central nervous system damage.NSAID (non-steroidal anti-inflammatory drug) is having under active peptic ulcer, the gastrointestinal hemorrhage situation definitely forbidding, and the Phenylbutazone medication is as short as and 3 weeks also can causes serious granulocytopenia or aplastic anemia.Aspect the treatment of hyperuricemia, whether doctor trained in Western medicine needs to have dispute with the uric acid resisting medicine to prevent recurrence for a long time with hyperuricemia to the gout patient always.Because of the uric acid resisting medicine does not all have analgesic, analgesia, antiinflammatory action, not only unhelpful to the arthritis of acute attack, instead can increase the weight of symptom or prolong the course of disease, and single early stage with the treatment of uric acid resisting medicine, the possibility of bringing out the gout acute attack is arranged.In recent years, the clinical report of using the traditional Chinese medical herbal treatment primary disease is increasing, and has obtained good curative effect.
The Chinese patent medicine of treatment gout does not almost have at present, the patent of Chinese medicine and research report are few, be mainly treatment and prevention gout, show the curative effect of anti-inflammatory and antalgic or uric acid resisting aspect, and be blank at Chinese medicine medicine that all has significant curative effect aspect antiinflammatory, analgesia and the uric acid resisting three or compositions at acute gout disease feature.(Li Bin is etc. the clinical experimental research of. powder for curing gout treatment acute gouty arthritis, the Tianjin traditional Chinese medical science, 2002,19 (4): 18) for [1] Zhang Ming, Jin Ruomin as powder for curing gout; [2] Zhang Ming, Jin Ruomin, Li Bin.＜application number〉02138216) clinical total effective rate 95%, zoopery has analgesia and antiinflammatory action.Anti-gout composition is applied for a patent less, be mainly total flavones, total alkaloids, volatile oil compositions ([3] Kong Lingdong, Wang Yemin, Zhu Jixiao.＜application number 02138216; [4] Kong Lingdong, Wang Yemin, Zhu Jixiao.＜application number〉200410034933), aspect the reduction metabolic arthritis remarkable drug effect is being arranged, but be not presented at the drug effect of antiinflammatory, analgesic activity aspect.
Three, summary of the invention
1. goal of the invention
The objective of the invention is the disease characteristics of showing effect repeatedly at acute gout metabolic arthritis, arthritis, all have the Chinese medicine medicine of significant curative effect or the present situation that compositions lacks aspect antiinflammatory, analgesia and the uric acid resisting three, providing a kind of acute gout for the treatment of at the compositions and the extracting method that all have the Chinese medicine extract of remarkable drug effect aspect antiinflammatory, analgesia, the uric acid resisting three.
2. technical scheme
A kind of pharmaceutical composition for the treatment of acute gout is characterized in that it is each effective constituents from crude drug Cortex Phellodendri, Rhizoma Atractylodis, Radix Achyranthis Bidentatae, Semen Coicis, Rhizoma Smilacis Glabrae, Caulis Lonicerae extract, makes by following umber proportioning:
Alkaloid 1.0-3.0 part, volatile oil 1.0-3.0 part, saponin 1.0-6.0 part
Organic acid 0.5-2.0 part flavone 0.6-2.0 part, aqueous saccharide 2.0-5.0 part
A kind of all kinds of extraction of effective components of pharmaceutical composition for the treatment of acute gout, its extraction step is as follows:
A, Cortex Phellodendri extract (I):
Get Cortex Phellodendri 1-4 part and carry 4 times with 10 times of amount 50%～95% ethanol, extracting solution reclaims ethanol, uses 10%H 2SO 4Transfer pH2, leave standstill centrifugal, abandon precipitate supernatant, transfer pH7 with 10%NaOH, last macroporous resin column (HPD100) is washed to colourlessly, with 30%～70% ethanol elution, collects eluent, reclaim ethanol, get Cortex Phellodendri extract (I), include alkaloid 100%, saponin 15%;
B, extractive of volatile oil (II): get Rhizoma Atractylodis 1-3 part, Semen Coicis 1-2 part with steam distillation extraction 4～6 hours, get extractive of volatile oil (II), include volatile oil 100%;
C, other extract (III):
Get Rhizoma Atractylodis 1-2 part, Radix Achyranthis Bidentatae 1-4 part, Semen Coicis 1-2 part, Rhizoma Smilacis Glabrae 1-6 part, Caulis Lonicerae 1-6 part, measure 60%～80% ethanol extractions 4 times with 10 times, leave standstill centrifugal behind the extracting solution recovery ethanol, supernatant is recovered as concentrated solution, add 3～9 times of amount ethanol of 95% leave standstill centrifugal go to precipitate supernatant (III-1); Precipitation is partly with 0.5%～5%Na 2CO 3Dissolving, the centrifugal precipitation of abandoning, supernatant 10%H 2SO 4Transfer pH5, leave standstill the centrifugal precipitate (III-2) that gets, wherein III-1 contains saponin 70%, flavone 40%, organic acid 55%, aqueous saccharide 100%; Contain saponin 15% among the III-2, flavone 60%, organic acid 45%;
D, Cortex Phellodendri extract (I), extractive of volatile oil (II), supernatant (III-1) and precipitate (III-2) are merged simmer down tos pharmaceutical composition of the present invention in all kinds of content of effective ratios.
The content of each constituents sees the following form 1 in the former relatively prescription of each extract.
Contained each constituents in each extract of table 1
Figure C20051003904000041
*: be mainly water soluble ingredients such as saccharide.
The proportioning of each constituents is formed in the said composition: alkaloid contains 1.0～3.0 parts, 1.0～3.0 parts of volatile oil, 1.0～6.0 parts of saponin, 0.5～2.0 part of organic acid, 0.6～2.0 part of flavone, 2.0～5.0 parts of aqueous saccharides.
3. beneficial effect
The pharmaceutical composition of treatment acute gout of the present invention is that each effective constituents from Cortex Phellodendri, Rhizoma Atractylodis, Radix Achyranthis Bidentatae, Semen Coicis, Rhizoma Smilacis Glabrae, Caulis Lonicerae Six-element medicament extract is formed, each effective constituents is the compositions of total volatile oil, total alkaloids, total flavones, total saponins, total organic acids and part water liquid, has the effect of the serum uric acid level of significant antiinflammatory, analgesia and reduction metabolic arthritis mice through the pharmacodynamic experiment said composition; Clinical verification has the drug effect of treatment acute gout, and the internal energy remarkable gout symptom of improving of first quarter moon makes the metabolic arthritis level reduce to normal value, and total effective rate is 100%, and safety non-toxic.
Four, the specific embodiment
The pharmaceutical composition of embodiment 1. treatment acute gouts
Effective ingredient from crude drug Cortex Phellodendri, Rhizoma Atractylodis, Radix Achyranthis Bidentatae, Semen Coicis, Rhizoma Smilacis Glabrae, Caulis Lonicerae extract, make by following umber proportioning:
1 part of alkaloid, 1 part of volatile oil, 5 parts of saponin, 1 part of organic acid, 1 part of flavone, 5 parts of aqueous saccharides.
The pharmaceutical composition of embodiment 2. treatment acute gouts
Effective ingredient from crude drug Cortex Phellodendri, Rhizoma Atractylodis, Radix Achyranthis Bidentatae, Semen Coicis, Rhizoma Smilacis Glabrae, Caulis Lonicerae extract, make by following umber proportioning:
2 parts of alkaloids, 2 parts of volatile oil, 6 parts of saponin, 2 parts of organic acid, 2 parts of flavone, 4 parts of aqueous saccharides.
The extracting method of the pharmaceutical composition of embodiment 3. treatment acute gouts, its extraction step is as follows:
1, Cortex Phellodendri extract (I):
Get 10 times of amounts of 4 parts of usefulness of Cortex Phellodendri, 95% ethanol and carry 4 times, extracting solution reclaims ethanol, uses 10%H 2SO 4Transfer pH2, leave standstill centrifugal, abandon precipitate supernatant, transfer pH7 with 10%NaOH, last macroporous resin column (HPD100) is washed to colourlessly, use 50% ethanol elution, collects eluent, recovery ethanol must Cortex Phellodendri extract (I), includes alkaloid 100% and saponin 15%;
2, extractive of volatile oil (II): get 2 parts of 3 parts of Rhizoma Atractylodis, Semen Coicis and extracted 5 hours with steam distillation, extractive of volatile oil (II), include volatile oil 100%.
3, other extract (III):
Get 2 parts of Rhizoma Atractylodis, 2 parts of Radix Achyranthis Bidentataes, 1 part of Semen Coicis, 5 parts of Rhizoma Smilacis Glabraes, 5 parts of Caulis Loniceraes, measure 80% ethanol extractions 4 times with 10 times, extracting solution reclaims and to leave standstill behind the ethanol centrifugally, and supernatant is recovered as concentrated solution, the ethanol that adds 8 times of amounts 95% leave standstill centrifugal go to precipitate supernatant (III-1); Precipitation part 5%Na 2CO 3Dissolving, the centrifugal precipitation of abandoning, supernatant 10%H 2SO 4Transfer pH5, leave standstill and centrifugally must precipitate (III-2), wherein III-1 contains saponin 70%, flavone 40%, organic acid 55%, aqueous saccharide 100%; Contain saponin 15% among the III-2, flavone 60%, organic acid 45%.4, the compositions that Cortex Phellodendri extract (I), extractive of volatile oil (II), supernatant (III-1) and precipitate (III-2) is merged simmer down to medicine of the present invention in all kinds of content of effective ratios.
The proportioning of each effective constituents is formed in this pharmaceutical composition: 1.0 parts of alkaloids, 1.0 parts of volatile oil, 5.0 parts of saponin, 1.0 parts of organic acid, 1.0 parts of flavone, 5 parts of aqueous saccharides.
Embodiment 4. pharmacodynamics tests
1. prescription screening
1.1 prescription source
Investigation " prescription voluminous dictionary ", the clinical report of Chinese medicine gout is found over nearly 20 years, acute attack stage in gout, adopting " SIMIAO WAN " mostly is that Rhizoma Atractylodis, Cortex Phellodendri, Radix Achyranthis Bidentatae, Semen Coicis are as the basic square flavor treatment primary disease that adds, evident in efficacy, but the flavor medicine kind of being reported that adds is extremely disperseed.These add the flavor medicine and mainly contain heat and toxic materials clearing away medicine, heat-clearing and diuresis-promoting drug and blood-activating analgesic three major types by the effect branch, and the prescription structure with " SIMIAO WAN " matches just.The basic pathology of acute gout is characterized as damp invasion of lower energizer, and the hot stasis of blood is tied mutually.So treatment should be adopted clearing heat and expelling damp, removing toxic substances and promoting subsidence of swelling, blood-activating analgetic are method.Effect from " SIMIAO WAN ", just at the pathological characteristic of gout acute stage, but the efficacy of a drug still has certain shortcoming, so carry out adding flavor more, therefore, with " SIMIAO WAN " for square substantially, to add the flavor medicine, to be divided into three major types be heat and toxic materials clearing away medicine, heat-clearing and diuresis-promoting drug, blood-activating analgesic, select more, the no obvious toxic-side effects of every apoplexy due to endogenous wind occurrence number, abundant, the moderate medicine in medicine source, form four directions, that is: gout I side respectively: substantially just+heat and toxic materials clearing away medicine
Gout II side: substantially just+heat-clearing and diuresis-promoting drug
Gout III side: substantially just+blood-activating analgesic
Gout IV side: substantially just+heat and toxic materials clearing away medicine+heat-clearing and diuresis-promoting drug+blood-activating analgesic
Substantially square: Cortex Phellodendri+Rhizoma Atractylodis+Radix Achyranthis Bidentatae+Semen Coicis carries out medicine efficacy screening.
1.2 the medicine efficacy screening of anti-experimental character gout research
According to " new drug research guide " method, induce rat acute gout model with uric acid sodium crystallite, with the positive medicine of indometacin, these four groups of prescription drugss are carried out the arthritic drug effect of gout relatively.
Animal: male SD rat, 48,200 ± 20g.
Method:
Four groups of medicine difference water boiling concentration are to 3g/ml;
Rat is divided into six groups of model group, positive group, I sample group, II sample group, III sample group, IV sample groups etc., 8 every group.Respectively indomethacin, I sample, II sample, III sample, IV sample are irritated to positive group, I sample group, II sample group, III sample group, IV sample group, continuous irrigation 5 days.After irritating stomach on the 5th day, measure the right back sufficient volume of rat, record respectively with Mus foot volume determination device.In right back sufficient intradermal injection MSU0.1m1/ (100mg/ml), writing time.Measure the right back sufficient volume of rat behind 1h, 2h, 3h, 4h, 5h, the 6h respectively, record.Calculate the foot swelling rate.
Figure C20051003904000061
Result: the results are shown in Table 2.I side is that SIMIAO WAN adds heat and toxic materials clearing away medicine (Cortex Phellodendri, Rhizoma Atractylodis, Radix Achyranthis Bidentatae, Semen Coicis, Rhizoma Smilacis Glabrae, Caulis Lonicerae) and model group relatively has significant difference, has the drug effect of significant anti-experimental character gout.
The screening experiment result of table 2SMF (021220) gout effect
1 hour 2 hours 3 hours 4 hours 5 hours 6 hours
Model group 0.189± 0.09 0.189± 0.06 0.222± 0.05 0.222± 0.09 0.234± 0.05 0.197± 0.08
The indometacin group 0.029± 0.035** 0.037± 0.017** 0.028± 0.020** 0.028± 0.036** 0.071± 0.067** 0.054± 0.063**
No. 1 side 0.060± 0.025** 0.100± 0.062* 0.116± 0.042** 0.115± 0.058* 0.133± 0.069** 0.142± 0.070
No. 2 sides 0.065± 0.051** 0.140± 0.074 0.154± 0.081 0.196± 0.082 0.165± 0.065* 0.173± 0.082
No. 3 sides 0.105± 0.054* 0.173± 0.060 0.197± 0.066 0.232± 0.043 0.252± 0.060 0.254± 0.063
No. 4 sides 0.072± 0.068* 0.097± 0.057** 0.132± 0.063* 0.137± 0.094 0.163± 0.085 0.189± 0.108
*P＜0.05；**P＜0.01
1.3 maximum dosage-feeding (MTD) experiment
Be safety, avirulence of determining each prescription, to just having carried out the MTD experiment screening everywhere.
Method:
The extract drugs method is the same;
Get 50 of healthy Kunming mouses, body weight 18-22g, male and female half and half.Be divided into five groups at random: (1) A side 4.5g (crude drug) ml -1(2) B side 4.5g (crude drug) ml -1(3) C side 4.0g (crude drug) ml -1(4) D side 3.8g (crude drug) ml -1(5) blank group.Fasting (can't help water) after 12 hours before the experiment is used twice gastric infusion in the Cmax one day in four directions respectively, each 0.35ml/10g.Observe a week continuously, record is tried situations such as mice behavior, activity, food ration, body weight, feces, death, and not dead mice is put to death after a week and performs an autopsy on sb.50 mices being tried saw that the mice hair color was smooth, feces is pale brown color the same day, and quality is rare soft, but ingest, movable less, mice activity after second day, food ration, body weight gain, feces etc. all recover normally, with blank group comparison no significant difference; And do not have dead and other unusual generation in the week, five groups perform an autopsy on sb after putting to death simultaneously, and each main organs (heart, liver, spleen, lung, kidney) changes through the perusal no abnormality seen, with blank group no significant difference relatively.
Table 3 adds the experimental result of the four wonderful recipe MTD that distinguish the flavor of
Figure C20051003904000081
Result: the results are shown in Table 3.Acute toxicity testing proves that four prescriptions all do not have tangible toxic reaction, have higher safety.
2, clinical verification
Diagnostic criteria: in " new Chinese medicine clinical research guideline ", the clinical research of new Chinese medicine treatment gout is a guideline, with reference to the Western medicine diagnose standard.The ancestral is rare by the Rheumatism Dept. director of Jiangsu Province's Changzhou institute of traditional Chinese medicine money, treats 10 routine acute gout patients with adding the flavor SIMIAO WAN, and clinical observation result sees Table 4.
Table 4 clinical treatment acute gout efficacy result
Figure C20051003904000082
Symptom: in nothing=0 light=1=2 heavy=3
The result:
Effective percentage is 100%, and obvious effective rate is 60%.
10 routine gout metabolic arthritis patients have 9 routine blood uric acids to drop to below the normal value (415umol/L), 1 example are arranged near normal value.
3. the experimentation of all kinds of component extract drug effects of writing out a prescription
Study this prescription effective site activity with mouse corrosion disease, analgesia and uric acid resisting effect experiment.
3.1 all kinds of component extracts
Alkaloid extract:
Extractive of volatile oil:
Saponin extract:
Flavone extract:
The organic acid extract:
Water liquid part: be mainly saccharide.
The content of all kinds of component extracts is consistent with prescription drugs, and their content and extract purity in prescription see Table 5.
Each extract yield of table 5 and purity
Figure C20051003904000091
3.2 each constituents combined method
By two levels, 7 factors design orthogonal design table, 1---this composition is arranged; 0---do not have this composition and see Table 6.
Table 6 adds flavor four wonderful recipe compositions combination orthogonal array L 8(2 7)
Figure C20051003904000092
A. flavone, saponin, organic acid, volatile oil, alkaloid, water liquid composition (being mainly saccharide);
B. alkaloid, saponin, organic acid;
C. flavone, volatile oil, alkaloid;
D. alkaloid, water-soluble composition;
E. saponin, volatile oil, water liquid composition;
F. saponin, flavone;
G. organic acid, volatile oil;
H. organic acid, flavone, water liquid composition.
3.3 effect experiment method
Positive drug: indomethacin
3.3.1 the antiinflammatory of the ear swelling due to toluene experiment
Divide 8 groups at random with mice, gavage respectively that normal saline, indomethacin, prescription, alkaloid, organic acid, saponin, water layer portion are sent out, volatile oil, continuous three days, 45min after administration in the 3rd day, be coated with dimethylbenzene 0.05ml/ in the mouse right ear two sides and only cause swollenly, left ear is not painted with normal ear.Take off cervical vertebra behind the 45min and put to death mice, lay disk in same area respectively, scales/electronic balance weighing, every Mus auris dextra weight-left ear weight=swelling degree with the 9mm punching.
3.3.2 acetic acid causes the analgesic experiment of chemical irritation
Divide 8 groups at random with mice, gavage normal saline, indomethacin, former side, alkaloid, flavone, organic acid, saponin, water soluble ingredient, volatile oil respectively, 0.5h lumbar injection 0.7% acetic acid 0.2ml/ only observes mice and turns round the body number of times because of pain causes in the time of turning round body and the 20min for the first time after the administration.
Annotate: turn round body with draw the abdomen simultaneously, the Mus body is bent into index.
3.3.3 influence to mice metabolic arthritis model
Mice is divided into blank group, model group, full side group, all kinds of component extract combination group.Blank group and model group give the equal-volume normal saline.Continuous three days, 1h after the administration except that the blank group, injected hypoxanthine 5mg/10g (0.2ml/10g)+subcutaneous injection uric acid enzyme inhibitor 0.5mg/10g (0.1ml/10g) to each group mouse peritoneal for the third time.1h, 3h after modeling get blood 0.3ml to mice, and be centrifugal, gets serum, surveys the hematuria acid number.
3.4 experimental result
3.4.1 each extract antiinflammatory action
Experimental result sees Table 7, six positions and all has antiinflammatory action, and its antiinflammatory suppression ratio is close with prescription drugs, and is wherein, the strongest with the antiinflammatory inhibitory action at flavone position.Compare with model control group, alkaloid, flavone, saponin position xylol induced mice ear swelling have extremely significantly inhibitory action (* * P＜0.01), and there is remarkable inhibitory action (* P＜0.05) at organic acid, volatile oil, water liquid position.
Each position antiinflammatory action result of table 7 (X ± S)
Annotate: * and matched group be P＜0.05 relatively; * and matched group be P＜0.01 relatively
3.4.2 each extract analgesic activity
Experimental result sees Table 8, and each position all has analgesic activity, but the analgesia suppression ratio all obviously is weaker than prescription drugs, and is wherein the strongest with the analgesic activity at organic acid position, close with positive control.Compare with model group, there is the analgesic activity (P＜0.01) of utmost point significance at water liquid position, organic acid position, and the alkaloid group has remarkable analgesic activity (P＜0.05).Flavone position, saponin position, volatile oil part no statistical significance.
Each position analgesic activity result of table 8
Figure C20051003904000112
Annotate: * and matched group be P＜0.05 relatively; * and matched group be P＜0.01 relatively
3.4.3 all kinds of component composition drug effects
3.4.4 analgesic activity
Method is the same, the results are shown in Table 9.
Turn round the analgesic activity (X ± SD) of body due to the table 9SMF Dichlorodiphenyl Acetate
Figure C20051003904000121
Compare * P＜0.05, * * P＜0.01 with model group.
The result shows that turn round body time number average and be starkly lower than model group full side, A side and F side, and significant difference (P＜0.01) is arranged; Relatively there is certain difference (P＜0.05) D side with model group.
3.4.5 antiinflammatory action
The results are shown in Table 10
Table 10 xylol causes the experimental result (X ± SD) of the antiinflammatory action of mice ear
Figure C20051003904000122
Compare with the blank group: * P＜0.05; * P＜0.01
Experimental result shows (table 10): the ear swelling due to full side group, positive group, combination A, combination C, combination D, combination E and the blank group comparison xylol has significant inhibitory effect (P＜0.01), and combination B, combination F, combination G, combination H and blank relatively have the ear swelling inhibitory action (P＜0.05) due to the xylol.
3.4.6 uric acid resisting effect
Table 11SMF is to the influence of metabolic arthritis mice blood uric acid
Figure C20051003904000131
Compare with the blank group, ▲P＜0.05, ▲ ▲P＜0.01; Compare *＜0.05, * * P＜0.01 with model group.
The result shows (seeing Table 11), and model group mice serum uric acid level apparently higher than the blank group, has significant difference (P＜0.01) at 1h, 3h place; Full side group has significant difference (P＜0.01) in 1h, 3h place and model group; A side's group is starkly lower than model group (P＜0.01) at 1h place blood uric acid, at 3h place and model group certain difference (P＜0.05) is arranged also; C side's group also is lower than model group (P＜0.05) at the 3h place; E side's group at 1h, 3h place all with model group have certain difference (P＜0.05 〉; G side's group 1h place and model group have certain difference (P＜0.05 〉.
3.5 conclusion:
The A compositions is that the compositions of alkaloids extract, volatile oil extract, saponins extract, flavone extract, organic acid extract and aqueous saccharide is all having remarkable activity aspect antiinflammatory, analgesia and the uric acid resisting.

Claims (1)

1. pharmaceutical composition for the treatment of acute gout is characterized in that it is by each effective constituents in crude drug Cortex Phellodendri, Rhizoma Atractylodis, Radix Achyranthis Bidentatae, Semen Coicis, Rhizoma Smilacis Glabrae, the Caulis Lonicerae extract, makes by following umber proportioning:
Alkaloid 1.0-3.0 part, volatile oil 1.0-3.0 part, saponin 1.0-6.0 part,
Organic acid 0.5-2.0 part, flavone 0.6-2.0 part, aqueous saccharide 2.0-5.0 part.
Each above-mentioned effective constituents derives from respectively in the following extracts of bulk drugs and obtains:
A, alkaloid and saponin obtain from Cortex Phellodendri extract I:
Get Cortex Phellodendri 1-4 part and carry 4 times with 10 times of amount 50%～95% ethanol, extracting solution reclaims ethanol, uses 10%H 2SO 4Transfer pH2, leave standstill centrifugal, abandon precipitate supernatant, transfer pH7 with 10%NaOH, last macroporous resin column is washed to colourlessly, with 30%～70% ethanol elution, collects eluent, recovery ethanol must Cortex Phellodendri extract I, includes alkaloid 100%, saponin 15%;
B, volatile oil obtain from the extract (II) of Rhizoma Atractylodis and Semen Coicis: get Rhizoma Atractylodis 1-3 part, Semen Coicis 1-2 part with steam distillation extraction 4～6 hours, get extractive of volatile oil II, include volatile oil 100%;
C, saponin, flavone, organic acid, aqueous saccharide obtains from Rhizoma Atractylodis, Radix Achyranthis Bidentatae, Semen Coicis, Rhizoma Smilacis Glabrae, Caulis Lonicerae extract III:
Get Rhizoma Atractylodis 1-2 part, Radix Achyranthis Bidentatae 1-4 part, Semen Coicis 1-2 part, Rhizoma Smilacis Glabrae 1-6 part, Caulis Lonicerae 1-6 part, measure 60%～80% ethanol extractions 4 times with 10 times, leave standstill centrifugal behind the extracting solution recovery ethanol, supernatant is recovered as concentrated solution, add 3～9 times of amount ethanol of 95% leave standstill centrifugal go to precipitate supernatant (III-1); Precipitation is partly with 0.5%～5%Na 2CO 3Dissolving, the centrifugal precipitation of abandoning, supernatant 10%H 2SO 4Transfer pH5, leave standstill the centrifugal precipitate (III-2) that gets, wherein contain saponin 70%, flavone 40%, organic acid 55%, aqueous saccharide 100% among the supernatant III-1, contain saponin 15% among the precipitate III-2, flavone 60%, organic acid 45%;
D, Cortex Phellodendri extract (I), extractive of volatile oil (II), supernatant (III-1) and precipitate (III-2) merged by the umber proportioning of above-mentioned each effective constituents be condensed into pharmaceutical composition of the present invention.
CNB2005100390408A 2005-04-25 2005-04-25 Pharmaceutical composition for treating acute gout and its extraction method Active CN100400082C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100390408A CN100400082C (en) 2005-04-25 2005-04-25 Pharmaceutical composition for treating acute gout and its extraction method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100390408A CN100400082C (en) 2005-04-25 2005-04-25 Pharmaceutical composition for treating acute gout and its extraction method

Publications (2)

Publication Number Publication Date
CN1698858A CN1698858A (en) 2005-11-23
CN100400082C true CN100400082C (en) 2008-07-09

Family

ID=35475212

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100390408A Active CN100400082C (en) 2005-04-25 2005-04-25 Pharmaceutical composition for treating acute gout and its extraction method

Country Status (1)

Country Link
CN (1) CN100400082C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101991792B (en) * 2009-08-18 2013-08-07 青岛海川创新生物天然药物研究中心 Traditional Chinese medicinal composition for treating gout and preparation method thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103436415B (en) * 2013-08-30 2015-07-15 杨贵庭 Healthcare medicinal liquor
CN104586852A (en) * 2014-12-30 2015-05-06 新昌县大成生物科技有限公司 Drug composition containing Vernavosine and application thereof
CN105250266A (en) * 2015-11-02 2016-01-20 淄博齐鼎立专利信息咨询有限公司 Application of Hirsutellone B in preparing medicine for curing acute gout
CN108992599A (en) * 2017-06-07 2018-12-14 徐定清 A kind of medicine pill for the Allopurinol that dehumidifies
CN107715014A (en) * 2017-10-31 2018-02-23 南宁市共健源健康科技有限公司 A kind of Chinese medicine composition for gout and preparation method thereof
CN111494508B (en) * 2020-03-25 2022-03-01 广西冠硕科技有限公司 Preparation method of traditional Chinese medicine gout plaster and product thereof
CN114601902A (en) * 2020-12-08 2022-06-10 安劲海 Traditional Chinese medicine formula for treating hyperuricemia and gout
CN114129675B (en) * 2021-12-29 2023-05-09 中国药科大学 Traditional Chinese medicine composition and application thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
制备工艺对加味四妙散总生物碱含量的影响. 吕高虹，尹莲，沈丽丽.时珍国医国药，第2卷. 2004
制备工艺对加味四妙散总生物碱含量的影响. 吕高虹，尹莲，沈丽丽.时珍国医国药，第2卷. 2004 *
加味丸与秋水仙碱治疗痛风性关节炎急性发作的随机对比观察. 王立新.现代康复，第5卷第9期. 2001
加味丸与秋水仙碱治疗痛风性关节炎急性发作的随机对比观察. 王立新.现代康复，第5卷第9期. 2001 *
四妙丸子加味治疗急性痛风性关节炎概述. 尹莲，史欣德.中国中医药科技，第11卷第1期. 2004
四妙丸子加味治疗急性痛风性关节炎概述. 尹莲，史欣德.中国中医药科技，第11卷第1期. 2004 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101991792B (en) * 2009-08-18 2013-08-07 青岛海川创新生物天然药物研究中心 Traditional Chinese medicinal composition for treating gout and preparation method thereof

Also Published As

Publication number Publication date
CN1698858A (en) 2005-11-23

Similar Documents

Publication Publication Date Title
CN100400082C (en) Pharmaceutical composition for treating acute gout and its extraction method
CN100348248C (en) Chinese medicinal composition for treating gout and its preparing process
CN101199683B (en) Chinese medicine for treating skin disease and preparing method thereof
CN101810715B (en) New application of fructus evodiae and extracts and compounds thereof
CN103386022A (en) Chinese medicine composition for treating tuberculous pleurisy
CN101584810B (en) Medicine composition for treating gastritis and peptic ulcer and preparation method thereof
CN1330328C (en) Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof
CN104257800B (en) A kind of medicament of Acne treatment
CN105168284A (en) Application of panax japonicus saponins V and total panax japonicus saponins thereof to preparation of medicament for resisting urathritis
CN101461831A (en) Geranium extract
CN104523925A (en) Traditional Chinese medicinal composition and its application in defecation promotion
CN1579485B (en) Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method
CN103157048B (en) Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof
CN100367997C (en) Medicine for treating arthrolithiasis and preparing method thereof
CN101884664B (en) Medicinal composition for preventing and treating rheumatoid arthritis and preparation method thereof
CN105641029A (en) Pharmaceutical composition for treating BOO (bladder outlet obstruction) and preparation method of pharmaceutical composition
CN1631388A (en) Chinese traditional medicine for treating chronic prostatitis
CN103520684A (en) Traditional Chinese medicine compound for reducing blood sugar
CN116726083B (en) Traditional Chinese medicine composition for treating chronic prostatitis
CN115040576B (en) Pharmaceutical composition for treating acute pancreatitis
CN1301125C (en) Medicine for treating gastrointestinal tract disease
CN106619765A (en) Pharmaceutical composition containing Marsdenia tenacissima extract product
CN102688254B (en) Medicinal composition for treating chronic diarrhea and preparation method and use thereof
CN102846759A (en) Pharmaceutical composition for treating acute and chronic prostatitis and preparation method thereof
CN1899428B (en) Chinese medicine preparation for treating pain and its preparing method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant